Skip to main content

Clinical trial VIOLETTE

A Phase II, Open Label, randomized, Multi-center Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR-Related Genes (including BRCA 1/2) (VIOLETTE)

Organ sein
Trial status Trial open for recruitment
Trial type
Interventionnal with IMP
Phase Trial phase 2
Academic trial Non
Sponsor AstraZeneca
EudraCT Identifier 2017-002361-22
Inclusion criteria Progressive. At least 1 line of athracycline and/or taxane
Last update